2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

被引：288
|
作者：
Das, Sandeep R. [1 ]
Everett, Brendan M. [2 ]
Birtcher, Kim K. [3 ]
Brown, Jenifer M. [4 ]
Januzzi, James L., Jr. [5 ]
Kalyani, Rita R. [6 ]
Kosiborod, Mikhail [7 ,8 ]
Magwire, Melissa [9 ]
Morris, Pamela B. [10 ,11 ]
Neumiller, Joshua J. [12 ,13 ]
Sperling, Laurence S. [14 ,15 ,16 ]
机构：
[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77004 USA
[4] Brigham & Womens Hosp, Cardiol, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA 02115 USA
[6] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21218 USA
[7] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[8] Univ Missouri Kansas City, Med, Kansas City, MO USA
[9] St Lukes Hlth Syst, Cardiometabol Ctr Alliance, Kansas City, MO USA
[10] Med Univ South Carolina, Seinsheimer Cardiovasc Hlth Program, Columbia, SC USA
[11] Med Univ South Carolina, Womens Heart Care, Columbia, SC USA
[12] Washington State Univ, Pullman, WA 99164 USA
[13] Washington State Univ, Pharmacotherapy, Pullman, WA 99164 USA
[14] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA
[15] Emory Univ, Atlanta, GA 30322 USA
[16] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Global Hlth, Atlanta, GA 30322 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 09期
关键词：
ACC Expert Consensus Decision Pathway; atherosclerotic cardiovascular disease; cardiovascular risk reduction; diabetes; GLP-1RA; SGLT2; inhibitor; type; 2; PEPTIDE-1 RECEPTOR AGONISTS; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; HEART-FAILURE; 2019; METHODOLOGY; GLUCOSE CONTROL; DOUBLE-BLIND; EMPAGLIFLOZIN; DISEASE; OUTCOMES;
D O I：
10.1016/j.jacc.2020.05.037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1117 / 1145
页数：29
相关论文
共 50 条
  • [31] Chinese expert consensus on the management of hypertension in adults with type 2 diabetes
    Pan, Xiaohui
    He, Hongbo
    Bao, Yuqian
    Bi, Yan
    Chen, Luyuan
    Chen, Xiaoping
    Fang, Hui
    Feng, Wenhuan
    Gao, Ling
    Guo, Lixin
    Guo, Yifang
    Han, Yaling
    Hua, Qi
    Li, Nanfang
    Li, Quanmin
    Li, Yan
    Li, Yong
    Li, Xialian
    Liu, Jing
    Ma, Huijuan
    Mu, Jianjun
    Nong, Kailei
    Shang, Huiqian
    Shen, Yunfeng
    Shi, Zhongwei
    Sun, Fang
    Sun, Ningling
    Tao, Jun
    Wang, Jiguang
    Wang, Xinling
    Wu, Jing
    Xiao, Xinhua
    Xie, Liangdi
    Xu, Jing
    Xu, Jing
    Ye, Hongying
    Yu, Dongni
    Yuan, Hong
    Zhang, Huijie
    Zhang, Jian
    Zhang, Lili
    Zhang, Yuqing
    Zhou, Jiaqiang
    Zhou, Xinli
    Zhu, Dalong
    Zhu, Tiehong
    Li, Sheyu
    Zhu, Zhiming
    JOURNAL OF EVIDENCE BASED MEDICINE, 2024, 17 (04) : 851 - 864
  • [32] Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
    Husain, Mansoor
    Bain, Stephen C.
    Jeppesen, Ole K.
    Lingvay, Ildiko
    Sorrig, Rasmus
    Treppendahl, Marianne B.
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2020, 22 (03) : 442 - 451
  • [33] Bromocriptine-QR: A Potential Novel Strategy for Cardiovascular Risk Reduction in Type 2 Diabetes
    Chamarthi, Bindu
    Ezrokhi, Michael
    Cincotta, Anthony H.
    CIRCULATION, 2013, 128 (22)
  • [34] Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes
    Strain, W. David
    Down, Su
    Brown, Pam
    Puttanna, Amar
    Sinclair, Alan
    DIABETES THERAPY, 2021, 12 (05) : 1227 - 1247
  • [35] Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies
    Zoungas, Sophia
    Patel, Anushka
    YEAR IN DIABETES AND OBESITY, 2010, 1212 : 29 - 40
  • [36] Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
    Thein, David
    Christiansen, Mia Nielsen
    Mogensen, Ulrik Madvig
    Bundgaard, Johan Skov
    Rorth, Rasmus
    Madelaire, Christian
    Fosbol, Emil Loldrup
    Schou, Morten
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Kober, Lars
    Kristensen, Soren Lund
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [37] Lipid management for cardiovascular risk reduction in type 1 diabetes
    Tell, Shoshana
    Nadeau, Kristen J.
    Eckel, Robert H.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (04) : 207 - 214
  • [38] Predictor for cardiovascular risk in patients with type-2 diabetes mellitus
    Azharuddin, Md
    Kapur, Prem
    Mishra, Ritu
    Saleem, Shakir
    Gupta, Ashok Kumar
    Adil, Mohammad
    Sharma, Manju
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 12
  • [39] Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes
    Motairek, Issam
    Al-Kindi, Sadeer
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 135 - 147
  • [40] Type 2 diabetes and cardiovascular risk factors
    Sharma, Morali D.
    Farmer, John Alan
    Garber, Alan
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 : 1 - 5
12345